Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 8/2019

21.05.2019 | Image of the Month

Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617

verfasst von: Mike M. Sathekge, Frank Bruchertseifer, Ismaheel O. Lawal, Mariza Vorster, Otto Knoesen, Thabo Lengana, Tebatso G. Boshomane, Kgomotso K. Mokoala, Alfred Morgenstern

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Excerpt

Brain metastases are not common in prostate cancer; they typically occur in patients with end-stage disease who are castrate-resistant. Patients with brain metastases have very limited survival [ 1]. Traditionally, the mainstays of therapy have been surgical resection, chemotherapy and external beam radiotherapy. Recently, combination of 177Lu-Prostate-specific membrane antigen (PSMA)-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer (mCRPC) showed significant regression in the sizes and PSMA-ligand avidity of the lesions over time [ 2]. Recent studies have demonstrated that targeted α-radiation therapy with 225Ac-PSMA-ligand can significantly benefit patients with mCRPC in the appropriate setting [ 3, 4]. Targeted α-radiation therapy may be more effective for the treatment of mCRPC, and has been shown, in a limited number of patients, to be effective in the setting of resistant to 177Lu-PSMA-617 therapy [ 5]. …
Literatur
1.
Zurück zum Zitat Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma: The M.D. Anderson Cancer Center experience. Cancer. 2003;98(2):363–8. CrossRefPubMed Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma: The M.D. Anderson Cancer Center experience. Cancer. 2003;98(2):363–8. CrossRefPubMed
2.
Zurück zum Zitat Wei X, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H. Combination of 177Lu-PSMA-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer. Clin Nucl Med. 2017;42(9):704–6. CrossRefPubMed Wei X, Schlenkhoff C, Schwarz B, Essler M, Ahmadzadehfar H. Combination of 177Lu-PSMA-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer. Clin Nucl Med. 2017;42(9):704–6. CrossRefPubMed
3.
Zurück zum Zitat Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59(5):795–802. CrossRefPubMed Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59(5):795–802. CrossRefPubMed
4.
Zurück zum Zitat Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. Morgenstern A. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46(1):129–38. CrossRefPubMed Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. Morgenstern A. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46(1):129–38. CrossRefPubMed
5.
Zurück zum Zitat Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941–4. CrossRefPubMed Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(12):1941–4. CrossRefPubMed
Metadaten
Titel
Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617
verfasst von
Mike M. Sathekge
Frank Bruchertseifer
Ismaheel O. Lawal
Mariza Vorster
Otto Knoesen
Thabo Lengana
Tebatso G. Boshomane
Kgomotso K. Mokoala
Alfred Morgenstern
Publikationsdatum
21.05.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04354-z

Weitere Artikel der Ausgabe 8/2019

European Journal of Nuclear Medicine and Molecular Imaging 8/2019 Zur Ausgabe

Letter to the Editor

Reply to the letter